Clinical Interests:
1. Dr. Alani is a board-certified dermatologist. She has a
clinical interest in melanocytic lesions, atypical nevi,
and melanoma and sees patients with these disorders.
2. Dr. Alani is currently involved in a clinical trials on
novel biomarkers for melanoma. She expects her laboratory work
will lead to the development of novel therapies for melanoma
which will result in early phase clinical trials within the
next few years.
Publications:
Alani, R.M., Hasskarl, J., Grace, M., Hernandez, M.-C., Israel,
M.A., Munger, K. Immortalization of primary human keratinocytes
by the helix-loop-helix protein, Id-1. Proceedings of the National
Academy of Sciences, U.S.A. 1999; 96:9637-9641.
Alani, R.M., Young, A.Z., Shifflett, C.B. Id1 regulation of
cellular senescence through transcriptional repression of p16/INK4a.
Proceedings of the National Academy of Sciences, U.S.A. 2001;
98(14):7812-7816.
Polsky, D., Young, A.Z., Busam, K.J., Alani, R.M. The transcriptional
repressor of p16/Ink4a, Id1 is upregulated in early melanomas.
Cancer Research 2001; 61(16): 6008-6011.
Volpert, O.V., Pili, R., Sikder, H.A., Zaichuk, T., Morris,C.,
Shiflett, C.B., Devlin, M.K., Conant, K., and Alani, R.M. Id1
regulates angiogenesis through transcriptional repression of
thrombospondin-1. Cancer Cell 2002; 2(6):473-83.
Volpert, O.V., and R. M. Alani. Wiring the angiogenic switch:
Myc, Ras, and Thrombospondin-1. Cancer Cell 2003; 3(3):199-200.
Sikder, H.A., Dunlap, S.D., Devlin, M., Ryu, B., and R.M. Alani.
Id proteins in cell growth and tumorigenesis. Cancer Cell 2003;
3(6):525-530.
Sikder, H.A., Huso, D.L., Zhang, H., Wang, B., Ryu, B., Hwang,
S.T., Powell, J.D., and Alani, R.M. Disruption of Id1 reveals
major differences in angiogenesis between transplanted and
autochthonous tumors. Cancer Cell 2003; 4:291-299.
Dunlap, S., Yu, X.-B., Cheng, L.-Z., Civin, C.I., and Alani,
R. M. High-efficiency stable gene transduction in primary human
melanocytes using a lentiviral expression system. Journal of
Investigative Dermatology 2004; 122:549-551.
Zheng, Y., Thompson, P.R., Cebrat, M., Wang, L., Devlin, M.K.,
Alani, R.M., and P.A. Cole. Selective HAT Inhibitors as Mechanistic
Tools for Protein Acetylation. Methods in Enzymology 2004;
376:188-99.
Alani, R.M., Silverthorn, C.F., and Orosz, K. Tumor Angiogenesis
in Mice and Men. Cancer Biology and Therapy 2004; 3(6):41-42.
Govindarajan B, Shah A, Cohen C, Arnold RS, Schechner J, Chung
J, Mercurio AM, Alani R, Ryu B, Fan CY, Cuezva JM, Martinez
M, Arbiser JL. Malignant transformation of human cells by constitutive
expression of platelet derived growth factor-BB (PDGF-BB).
J Biol Chem. 2005 Apr 8;280(14):13936-43.
Guidez, F., Howell, L., Isalan, M., Cebrat, M., Alani, R.M.,
Ivins, S., Hormaeche, I., McConnell, M.J., Pierce, S., Cole,
P.A. Licht, J., and A. Zelent. Histone acetyltransferase activity
of p300 is required for transcriptional repression by the Promyelocytic
Leukemia Zinc Finger protein. Molecular and Cellular Biology
2005; 25(13):5552-66.
Zheng, Y., Karanam, B., Cebrat, M., Buck, D., Devlin, M., Zelent,
A., Alani, R.M., and Cole, P.A. Synthesis and Evaluation of
a Selective Cell Permeable p300 Histone Acetyltransferase Inhibitor.
Journal of the American Chemical Society 2005; 127(49):17182-3.
Silverthorn CF and Alani RM. Defining the role of hypoxia in
melanoma development and response to therapy. Melanoma Research
2006; 16:S105.
Cummings, S., Ryu, B., and Alani RM. Defining the role of Id1
in melanoma development and progression. Melanoma Research
2006; 16:S77.
Fecher, L., Cummings, S, Keefe, M., and R.M. Alani. Towards
a Molecular Classification of Melanoma. Journal of Clinical
Oncology. 2006, In press.
Ryu, B., Kim, D., Albert, M., Dunlap, S., Fackler, M.J., Herman,
J., and Alani, R.M. Id1 expresion is transcriptionally regulated
in radial growth phase melanomas. Submitted manuscript
Ryu, B., Keefe, M.J., Kim, D., Meeker, A.K., and Alani, R.M.
Physiologic levels of BRAFE600 promote growth of primary human
melanocytes. Submitted manuscript. |
| |
|
|
